Which has better earnings and valuation, NKTX or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is NKTX or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Climb Bio N/A -31.79% -30.79%

Which has stronger valuation and earnings, ANNX or NKTX?

Annexon is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Nkarta N/A N/A -$104.08M -$1.57 N/A

Is ANNX or NKTX more profitable?

Nkarta's return on equity of -39.64% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Nkarta N/A -39.64% -30.45%

Is NKTX or DBVT more profitable?

Nkarta has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Nkarta's return on equity of -39.64% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% DBV Technologies -3,506.53% -119.33% -84.43%

Which has stronger earnings & valuation, NKTX or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A Design Therapeutics N/A N/A -$69.79M -$1.18 N/A

Is NKTX or DSGN more profitable?

Design Therapeutics' return on equity of -34.03% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Design Therapeutics N/A -34.03% -32.05%

Nkarta (NKTX) Competitors

$2.76 -0.19 (-6.44%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.74 -0.02 (-0.91%)

As of 07:00 AM Eastern

Compare

NKTX vs. CLYM, ANNX, DBVT, ACRS, and DSGN

Should you buy Nkarta stock or one of its competitors? Nkarta's main competitors and comparable companies include Climb Bio (CLYM), Annexon (ANNX), DBV Technologies (DBVT), Aclaris Therapeutics (ACRS), and Design Therapeutics (DSGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nkarta compare to Climb Bio?

Nkarta (NASDAQ:NKTX) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

80.5% of Nkarta shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nkarta has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

In the previous week, Climb Bio had 9 more articles in the media than Nkarta. MarketBeat recorded 9 mentions for Climb Bio and 0 mentions for Nkarta. Climb Bio's average media sentiment score of 0.49 beat Nkarta's score of 0.00 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Nkarta	Neutral
Climb Bio	Neutral

Climb Bio's return on equity of -31.79% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Climb Bio	N/A	-31.79%	-30.79%

Nkarta currently has a consensus target price of $11.20, suggesting a potential upside of 305.80%. Climb Bio has a consensus target price of $26.92, suggesting a potential upside of 115.04%. Given Nkarta's higher probable upside, equities research analysts plainly believe Nkarta is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Nkarta on 8 of the 14 factors compared between the two stocks.

How does Nkarta compare to Annexon?

Annexon (NASDAQ:ANNX) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

80.5% of Nkarta shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Annexon presently has a consensus target price of $15.14, indicating a potential upside of 291.29%. Nkarta has a consensus target price of $11.20, indicating a potential upside of 305.80%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Annexon has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Annexon is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

In the previous week, Annexon had 2 more articles in the media than Nkarta. MarketBeat recorded 2 mentions for Annexon and 0 mentions for Nkarta. Annexon's average media sentiment score of 0.37 beat Nkarta's score of 0.00 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Neutral
Nkarta	Neutral

Nkarta's return on equity of -39.64% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Nkarta	N/A	-39.64%	-30.45%

Summary

Nkarta beats Annexon on 8 of the 14 factors compared between the two stocks.

How does Nkarta compare to DBV Technologies?

Nkarta (NASDAQ:NKTX) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Nkarta has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, meaning that its share price is 195% less volatile than the broader market.

In the previous week, DBV Technologies had 2 more articles in the media than Nkarta. MarketBeat recorded 2 mentions for DBV Technologies and 0 mentions for Nkarta. DBV Technologies' average media sentiment score of 0.71 beat Nkarta's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Nkarta	Neutral
DBV Technologies	Positive

Nkarta presently has a consensus price target of $11.20, indicating a potential upside of 305.80%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 298.52%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts clearly believe Nkarta is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Nkarta has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
DBV Technologies	$5.64M	135.68	-$146.95M	-$3.51	N/A

Nkarta has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Nkarta's return on equity of -39.64% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nkarta beats DBV Technologies on 12 of the 15 factors compared between the two stocks.

How does Nkarta compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 0 mentions for Nkarta. Aclaris Therapeutics' average media sentiment score of 0.29 beat Nkarta's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aclaris Therapeutics	Neutral
Nkarta	Neutral

Aclaris Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Aclaris Therapeutics has higher revenue and earnings than Nkarta. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	93.93	-$64.92M	-$0.58	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

Nkarta has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Nkarta's return on equity of -39.64% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Nkarta	N/A	-39.64%	-30.45%

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aclaris Therapeutics presently has a consensus target price of $11.33, indicating a potential upside of 115.46%. Nkarta has a consensus target price of $11.20, indicating a potential upside of 305.80%. Given Nkarta's higher possible upside, analysts clearly believe Nkarta is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Aclaris Therapeutics beats Nkarta on 8 of the 15 factors compared between the two stocks.

How does Nkarta compare to Design Therapeutics?

Nkarta (NASDAQ:NKTX) and Design Therapeutics (NASDAQ:DSGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

80.5% of Nkarta shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Design Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

In the previous week, Nkarta's average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nkarta	Neutral
Design Therapeutics	Neutral

Nkarta has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

Nkarta presently has a consensus price target of $11.20, indicating a potential upside of 305.80%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 33.50%. Given Nkarta's higher probable upside, analysts plainly believe Nkarta is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics' return on equity of -34.03% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Design Therapeutics	N/A	-34.03%	-32.05%

Summary

Design Therapeutics beats Nkarta on 7 of the 11 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$211.29M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.76	13.88	274.06	25.69
Price / Sales	N/A	1,343.72	637.81	78.88
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.63	15.21	10.40	6.32
Net Income	-$104.08M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-1.78%	-1.72%	-0.69%	0.17%
1 Month Performance	6.56%	-6.17%	-3.18%	-3.27%
1 Year Performance	33.98%	30.66%	15.13%	5.58%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	2.4946 of 5 stars	$2.76 -6.4%	$11.20 +305.8%	+35.3%	$211.29M	N/A	N/A	106	Analyst Forecast High Trading Volume
CLYM Climb Bio	3.3 of 5 stars	$13.64 -2.9%	$26.92 +97.4%	+456.4%	$806.98M	N/A	N/A	29
ANNX Annexon	2.5849 of 5 stars	$4.22 -0.2%	$15.14 +258.8%	+33.0%	$801.92M	N/A	N/A	92
DBVT DBV Technologies	3.4461 of 5 stars	$12.10 -2.0%	$48.50 +300.8%	+30.2%	$776.54M	$5.64M	N/A	161	Positive News
ACRS Aclaris Therapeutics	1.9686 of 5 stars	$5.57 +1.3%	$11.33 +103.5%	+187.4%	$769.03M	$7.83M	N/A	73	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. CLYM, ANNX, DBVT, ACRS, and DSGN

How does Nkarta compare to Climb Bio?

Summary

How does Nkarta compare to Annexon?

Summary

How does Nkarta compare to DBV Technologies?

Summary

How does Nkarta compare to Aclaris Therapeutics?

Summary

How does Nkarta compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. CLYM, ANNX, DBVT, ACRS, and DSGN

How does Nkarta compare to Climb Bio?

Do insiders & institutionals hold more shares of NKTX or CLYM?

Which has more volatility and risk, NKTX or CLYM?

Does the media favor NKTX or CLYM?

Is NKTX or CLYM more profitable?

Do analysts prefer NKTX or CLYM?

Which has better earnings and valuation, NKTX or CLYM?

Summary

How does Nkarta compare to Annexon?

Do institutionals & insiders believe in ANNX or NKTX?

Do analysts rate ANNX or NKTX?

Which has more risk & volatility, ANNX or NKTX?

Which has stronger valuation and earnings, ANNX or NKTX?

Does the media refer more to ANNX or NKTX?

Is ANNX or NKTX more profitable?

Summary

How does Nkarta compare to DBV Technologies?

Which has more volatility & risk, NKTX or DBVT?

Does the media favor NKTX or DBVT?

Do analysts recommend NKTX or DBVT?

Which has preferable valuation & earnings, NKTX or DBVT?

Is NKTX or DBVT more profitable?

Do insiders & institutionals believe in NKTX or DBVT?

Summary

How does Nkarta compare to Aclaris Therapeutics?

Does the media prefer ACRS or NKTX?

Which has more risk & volatility, ACRS or NKTX?

Which has preferable valuation and earnings, ACRS or NKTX?

Is ACRS or NKTX more profitable?

Do insiders and institutionals believe in ACRS or NKTX?

Do analysts prefer ACRS or NKTX?

Summary

How does Nkarta compare to Design Therapeutics?

Do institutionals & insiders believe in NKTX or DSGN?

Which has stronger earnings & valuation, NKTX or DSGN?

Does the media favor NKTX or DSGN?

Which has more volatility & risk, NKTX or DSGN?

Do analysts prefer NKTX or DSGN?

Is NKTX or DSGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools